Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 12, 2012, Pages 7754-7759

  Comyn, Oliver ^a   Heng, Ling Zhi ^a   Ikeji, Felicia ^a   Bibi, Kanom ^a   Hykin, Philip G ^a   Bainbridge, James W ^a   Patel, Praveen J ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA OPACITY; DIABETIC MACULAR EDEMA; ERROR; FEMALE; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT REPEATABILITY; OBSERVER VARIATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA LUTEA; RETINAL THICKNESS; COMPARATIVE STUDY; DIABETIC RETINOPATHY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; RETINA MACULA EDEMA;

ADULT; AGED; AGED, 80 AND OVER; DIABETIC RETINOPATHY; FEMALE; HUMANS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84872198714     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10895     Document Type: Article

References (19)

1. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
2. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health. 2006;6:58.
3. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the Management of Diabetic Macular Edema (Bolt study) 12-month data: report 2. Ophthalmology. 2010;117:1078-1086.
4. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.
5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
6. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-2405.
7. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol. 2001;119:1135-1142.
8. Krzystolik MG, Strauber SF, Aiello LP, et al. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007;114:1520-1525.
9. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci. 2008;49:4290-4296.
10. Domalpally A, Gangaputra S, Peng Q, Danis RP. Repeatability of retinal thickness measurements between spectral-domain and time-domain optical coherence tomography images in macular disease. Ophthalmic Surg Lasers Imaging. 2010; 41(suppl):S34-S41.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
12. Bland M. How can I decide the sample size for a repeatability study? University of York. [User Web Areas]. 2010. Available at: http://www-users.york.ac.uk/~mb55/meas/sizerep.htm. Accessed May 17, 2010.
13. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
14. Patel PJ, Chen FK, Ikeji F, et al. Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49: 1084-1088.
15. Parravano M, Oddone F, Boccassini B, et al. Reproducibility of macular thickness measurements using Cirrus SD-OCT in neovascular age-related macular degeneration. Invest Oph-thalmol Vis Sci. 2010;51:4788-4791.
16. Lammer J, Scholda C, Prunte C, Benesch T, Schmidt-Erfurth U, Bolz M. Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. Retina. 2011;31:48-55.
17. Danis RP, Glassman AR, Aiello LP, et al. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol. 2006;124:1701-1707.
18. Kotsidis ST, Lake SS, Alexandridis AD, Ziakas NG, Ekonomidis PK. 24-Hour variation of optical coherence tomography-measured retinal thickness in diabetic macular edema. Eur J Ophthalmol. 2012;22:785-791.
19. Parravano M, Oddone F, Boccassini B, et al. Reproducibility of macular thickness measurements using Cirrus SD-OCT in neovascular age-related macular degeneration. Invest Oph-thalmol Vis Sci. 2010;51:4788-4791.